Forbes  Jun 27  Comment 
The Czech tennis star has signed a second jewelry deal as she chases a third Wimbledon title.
Mondo Visione  Jul 27  Comment 
The International Securities Exchange (ISE) today announced that it has introduced a new order type, the Add Liquidity Only Order (ALO). An ALO specifies that the order can only be executed if it adds liquidity to the order book as a “maker.”...
Benzinga  Mar 1  Comment 
On February 28, 2012, Pfizer Inc. (NYSE: PFE) notified DURECT Corporation, a Delaware corporation (NASDAQ: DRRX), that Pfizer is terminating, effective August 30, 2012, the Development and License Agreement between Alpharma Ireland Limited and...
Reuters  Apr 30  Comment 
King Pharmaceuticals Inc said it has completed its review of its Alpharma Animal Health business and has determined that it will not alter its current structure.
Wall Street Journal  Mar 16  Comment 
Alpharma agreed to pay $42.5 million to settle a whistleblower case over its promotion of the morphine drug Kadian.
New Straits Times  Feb 7  Comment 
KUALA LUMPUR: The government has allowed three foreign missions here to post an "airport liaison officer" (ALO) at the Kuala Lumpur International Airport (KLIA) to screen travellers to their respective countries.


Alpharma, Inc. (ALO) is a specialty pharmaceutical company with global operations in human and animal pharmaceuticals. Alpharma does business in more than 80 countries. The company struggled in 2004, based on continuing problems from manufacturing issues raised by the U.S. Food and Drug Administration (FDA) in 2003. Alpharma has since worked through the bulk of these problems, regaining FDA approval to begin solid dose and liquid formulation manufacturing. With its generic business out of the woods, the company decided it was time to divest these operations and focus more on growing its specialty pharmaceutical business. In December 2005, Alpharma concluded the sale of its U.S. and international generics business to Actavis Group for $810 million in cash. Soon thereafter, Alpharma sold ParMed Pharmaceuticals, its U.S. pharmaceutical distribution business, to Cardinal Health Inc. for $40.1 million in cash. Following the divestiture of its generic business, the company is now conducting its business through three main segments: Pharmaceuticals (formerly known as Branded Pharmaceuticals), Active Pharmaceutical Ingredients (API), and Animal Health. The API segment develops, manufactures, and markets a range of fermentation-based active pharmaceutical ingredients that are used, primarily by third parties, in the manufacture of finished-dose pharmaceutical products.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki